Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial.
Shuya LiRun-Qi WangqinYue-Song PanAoming JinHao LiLee H SchwammMarc FisherBruce C V CampbellMark W ParsonsZiran WangHongguo DaiDeyang LiRunhui LiJunhai WangDavid WangYilong WangXing-Quan ZhaoZixiao LiHuaguang ZhengYun-Yun XiongXia MengYong-Jun WangPublished in: Stroke and vascular neurology (2024)
In AIS patients who were treated with either tenecteplase or alteplase within 4.5 hours onset, there was no difference observed in the efficacy and safety between the two groups at the three different OTT time intervals.
Keyphrases
- clinical trial
- liver failure
- study protocol
- phase iii
- respiratory failure
- randomized controlled trial
- heavy metals
- phase ii
- open label
- acute ischemic stroke
- high dose
- drug induced
- type diabetes
- metabolic syndrome
- risk assessment
- low dose
- skeletal muscle
- adipose tissue
- insulin resistance
- weight loss
- replacement therapy
- glycemic control